Thomas McHugh - Avadel Pharmaceuticals Principal VP
| AVDL Stock | USD 11.22 0.44 3.77% |
VP
Thomas McHugh is Principal VP of Avadel Pharmaceuticals PLC
| Age | 59 |
| Address | 10 Earlsfort Terrace, Dublin, Ireland, 2 |
| Phone | 353 1 901 5201 |
| Web | https://www.avadel.com |
Thomas McHugh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas McHugh against Avadel Pharmaceuticals stock is an integral part of due diligence when investing in Avadel Pharmaceuticals. Thomas McHugh insider activity provides valuable insight into whether Avadel Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Avadel Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avadel Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas McHugh over three months ago Acquisition by Thomas McHugh of 2000 shares of Avadel Pharmaceuticals at 14.5 subject to Rule 16b-3 |
Avadel Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3445) % which means that it has lost $0.3445 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9952) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -1.03 this year. Return On Capital Employed is expected to rise to -1.02 this year. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 8.17 this year, although the value of Total Assets will most likely fall to about 134.2 M.Similar Executives
| Found 9 records | VP Age | ||
| Kipling Thacker | Lifecore Biomedical | 69 | |
| Michael JD | Intracellular Th | 51 | |
| Eric Frings | Dynavax Technologies | N/A | |
| Meredith Cook | ANI Pharmaceuticals | 50 | |
| MPH MD | Ironwood Pharmaceuticals | N/A | |
| Meredith JD | ANI Pharmaceuticals | 50 | |
| Paul Cox | Dynavax Technologies | N/A | |
| MBA MS | Ironwood Pharmaceuticals | N/A | |
| David JD | Alkermes Plc | 52 | |
Management Performance
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.34 |
Avadel Pharmaceuticals Leadership Team
Elected by the shareholders, the Avadel Pharmaceuticals' board of directors comprises two types of representatives: Avadel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avadel. The board's role is to monitor Avadel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Avadel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avadel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Kim, Chief Officer | ||
| Christian PharmD, Chief Affairs | ||
| Steven Sullivan, VP Operations | ||
| Gregory Davis, VP Development | ||
| Jason Vaughn, Senior Operations | ||
| Gregory Divis, Executive Vice President Chief Commercial Officer | ||
| Jennifer PharmD, Senior Affairs | ||
| Mark Elrod, Vice Sales | ||
| Jordan MD, Consultant | ||
| Angie Woods, Vice Culture | ||
| Jerad Seurer, General Secretary | ||
| Thomas McHugh, Principal VP |
Avadel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avadel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.06 B | ||||
| Shares Outstanding | 96.27 M | ||||
| Shares Owned By Insiders | 4.77 % | ||||
| Shares Owned By Institutions | 80.00 % | ||||
| Number Of Shares Shorted | 9.45 M | ||||
| Price To Earning | 61.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.